Monika Gaba, Punam Gaba, Sarbjot Singh, Neelima Dhingra
email@example.com , firstname.lastname@example.org
Monika Gaba1*, Punam Gaba1, Sarbjot Singh2, Neelima Dhingra3*
1Department of Pharmaceutical Sciences, ASBASJSM College of Pharmacy, Bela, Ropar, Punjab, India
2Drug Discovery Research, Panacea Biotech Pvt. Ltd., Mohali, Punjab, India.
3University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, India.
Volume - 5,
Issue - 1,
Year - 2015
Leukocyte function associated antigen-1 (LFA-1, CD11a/CD18, aLß2) is a cell surface adhesion protein expressed on leukocytes. Interaction of LFA-1 with its counter receptor intercellular adhesion molecule-1 (ICAM-1) promotes the migration of leukocytes to the site of inflammation and is responsible for a variety of cell adhesion events required for normal and pathological functions of the immune system. Thus, the LFA-1/ICAM-1 interaction is thought to play a role in the pathogenesis of inflammatory and auto-immune disease conditions such as psoriasis, multiple sclerosis, asthma, rheumatoid arthritis, inflammatory bowel disease and transplant rejection. LFA-1/ICAM-1 interaction inhibitors have been extensively studied as a therapeutic target for clinically important diseases; leading to the development of therapeutic antibodies, peptides, peptidomimetics, allosteric and competitive inhibitors. However, despite of promising preclinical results, the outcome of clinical trials with LFA-1/ICAM-1 interaction inhibitors has been inconsistent and met with limited clinical success. This article gives a brief account of rationale and efficacy of different LFA-1/ICAM-1interaction inhibitors as promising therapeutic strategy for surmounting inflammatory disorders.
Cite this article:
Monika Gaba, Punam Gaba, Sarbjot Singh, Neelima Dhingra. Inhibition of LFA-1/ICAM-1 Interaction: A Therapeutic Strategy for Surmounting Inflammation. Asian J. Pharm. Res. 5(1): Jan.-Mar. 2015; Page 37-47. doi: 10.5958/2231-5691.2015.00006.4
Monika Gaba, Punam Gaba, Sarbjot Singh, Neelima Dhingra. Inhibition of LFA-1/ICAM-1 Interaction: A Therapeutic Strategy for Surmounting Inflammation. Asian J. Pharm. Res. 5(1): Jan.-Mar. 2015; Page 37-47. doi: 10.5958/2231-5691.2015.00006.4 Available on: https://asianjpr.com/AbstractView.aspx?PID=2015-5-1-6